Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Non Operating Income (2019 - 2025)

Benitec Biopharma has reported Non Operating Income over the past 7 years, most recently at $19000.0 for Q4 2025.

  • Quarterly results put Non Operating Income at $19000.0 for Q4 2025, down 98.48% from a year ago — trailing twelve months through Dec 2025 was $731000.0 (down 29.37% YoY), and the annual figure for FY2025 was -$131000.0, up 35.78%.
  • Non Operating Income reached $19000.0 in Q4 2025 per BNTC's latest filing, down from $838000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $1.3 million in Q4 2024 and bottomed at -$513000.0 in Q3 2022.
  • Median Non Operating Income over the past 5 years was -$56000.0 (2023), compared with a mean of $25789.5.
  • The largest annual shift saw Non Operating Income crashed 1438.1% in 2021 before it skyrocketed 7931.25% in 2024.
  • Over 5 years, Non Operating Income stood at $14000.0 in 2021, then surged by 1321.43% to $199000.0 in 2022, then plummeted by 108.04% to -$16000.0 in 2023, then surged by 7931.25% to $1.3 million in 2024, then tumbled by 98.48% to $19000.0 in 2025.
  • Business Quant data shows Non Operating Income for BNTC at $19000.0 in Q4 2025, $838000.0 in Q3 2025, and -$126000.0 in Q2 2025.